12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Inotuzumab ozogamicin: Phase II data

An open-label Phase II trial in 54 evaluable patients with relapsed or refractory CD20- or CD22-positive DLBCL showed that 1.8 mg/m 2 IV inotuzumab ozogamicin every 21 days plus rituximab for up to 6 cycles led to an ORR of 35%. Specifically, 24% of patients achieved a complete response and 11% achieved a partial response, plus 13% of patients achieved stable disease. Additionally, inotuzumab...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >